Social Anxiety Disorder (SAD)
Conditions
Keywords
Social anxiety disorder, social phobia, positron emission tomography (PET, regional cerebral blood flow (rCBF), nefazodone, amygdala
Brief summary
The purpose of this study is to determine the effectiveness of nefazadone in patients with social anxiety disorder (SAD).
Detailed description
The purpose of this study is to examine the efficacy of the 5HT2 receptor antagonist nefazadone in SAD, and to explore regional cerebral blood flow in patients with SAD when confronted with a personal phobic stimulus, using positron emission tomography (PET). Changes in cerebral blood flow were correlated with self-rated anxiety measures.
Interventions
DRUGNefazodone
Sponsors
Bristol-Myers Squibb
Emory University
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* DSM-IV diagnosis of generalized social anxiety disorder, males and females between the ages of 18-65
Exclusion criteria
* A history of bipolar disorder, psychotic illness, or any other anxiety disorders, organic brain disease or active drug or alcohol abuse within one year as assessed by the SCID-P and interview, or a concurrent medical condition that would not be compatible with the study in the opinion of the principal investigator. Patients required to be free of psychotropic or beta-blocker medication for 2 weeks prior to study. Pts taking fluoxetine required to be drug-free for 6 weeks.
Countries
United States
Outcome results
None listed